Administrating docetaxel, doxorubicin, and cyclophosphamide as a neoadjuvant treatment may decrease lymphedema risk in breast cancer patients.
Role of endocrine therapy in weak estrogen/progesterone receptor expression in HER2 negative breast cancer.
Is there a role of breast pathologist in diagnostic challenges of discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis?
Detailed information about chemotherapy in breast control arm might affect cognitive sequelae compared with endocrine therapy patients.
Bisphosphonate-associated orbital inflammation: is it class-specific side effect?
Enhanced pre-operative axillary staging using intradermal microbubbles and contrast-enhanced ultrasound to detect and biopsy sentinel lymph nodes in breast cancer: Does molecular subtype matters?
Diagnosis of patients with inflammatory breast cancer is a problematic issue.
More predictive markers were identified for trastuzumab-induced cardiotoxicity.
Questions About In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy.
The Effect of Total Size of Lesions in Multifocal/Multicentric Breast Cancer on Survival.
In this study, we aimed to assess the prognostic performance of determining the T stage according to the total size of lesions compared with the size of the largest lesion in the breast in patients with multifocal/multicentric (MF/MC) breast cancer.
Does tacrolimus have any positive impact on outcome of post-transplant breast cancer patients?
Does Aspirin Decrease Risk of Specific Breast Cancer Subtype in Women with Diabetes?
The link between obesity and triple negative breast cancer.
Risk factors for development of breast cancer in premenopausal women with atypical ductal hyperplasia are more complicated.
Do systemic recurrences increase after the use of scalp cooling in patients treated for breast cancer with chemotherapy?
Is switching to tamoxifen the only choice of treatment for improving aromatase inhibitor toxicity?
Digital breast tomosynthesis findings may be different in HER2 positive breast cancer patients according to hormone receptor status.
Imaging modalities for the detection of distant metastases in breast cancer patients diagnosed in the 1970s and 1990s: Does it make any sense?
Prognostic effect of neutrophil-lymphocyte ratio during concurrrent chemo-radiotherapy period in glioblastoma patients who did not receive dexamethasone.
Taxane Followed by Anthracycline or Vice Versa: Impact of Sequential Order on Breast Cancer Recurrence?
Dose adjustment in obese breast cancer patients receiving neoadjuvant chemotherapy might have an impact on survival.
Duration of trastuzumab in HER2-positive metastatic breast cancer after complete remission: still debatable issue?
Tumor localization may change the type of adjuvant treatment in gastric cancer.
Is HER2 loss after neoadjuvant chemotherapy determinant for the choice of adjuvant treatment in HER2 positive breast cancer patients?
Questions about Ki67 staining in luminal breast cancer.
Prognosis of women with invasive pleomorphic lobular carcinoma compared with classical invasive lobular carcinoma: Still debatable issue?
Should patients with HER2 loss after neoadjuvant treatment still be treated with adjuvant trastuzumab treatment?
T1 invasive breast lobular tumor and ductal carcinoma with HER-2 positive characteristics: Is it rationale to use adjuvant trastuzumab?
Metastasis-acquired changes in clinically actionable genes in triple negative breast cancer patients with central nervous system metastases: Focus on HER2 targeted therapies.
Does the Tumor Size Affect the Signal Enhancement Ratio in Luminal Breast Cancers?